score_bin	sensitive_predictive_implication	resistance_predictive_implication	prognostic_predictive_implication	feature_type	feature	alteration_type	alteration	tumor_f	total_coverage	exac_af	exac_common	clinvar	sensitive_score_bin	sensitive_therapy_name	sensitive_therapy_type	sensitive_description	sensitive_citation	sensitive_url	resistance_score_bin	resistance_therapy_name	resistance_therapy_type	resistance_description	resistance_citation	resistance_url	prognostic_score_bin	favorable_prognosis	prognostic_description	prognostic_citation	prognostic_url	number_germline_mutations_in_gene	validation_total_coverage	validation_tumor_f	validation_detection_power	feature_display	preclinical_efficacy_observed	patient_id	tumor_sample_barcode	normal_sample_barcode
Putatively Actionable	Guideline	Guideline		Copy Number	AR	Amplification				0.0	0.0		Putatively Actionable	Abiraterone	Hormone therapy	Androgen receptor activation may predict sensitivity to second generation androgen deprivation or direct androgen inhibitors.	National Comprehensive Cancer Network. Prostate Cancer NCCN Evidence Blocks (Version 3.2016). Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/prostate_blocks.pdf	Putatively Actionable	Abiraterone	Hormone therapy	Androgen receptor activation is a potential mechanism of recurrence of prostate cancer during androgen deprivation therapy.	National Comprehensive Cancer Network. Prostate Cancer NCCN Evidence Blocks (Version 3.2016). Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/prostate_blocks.pdf						0				AR Amplification		PROS10448-1115154	PROS10448-1115154-Tumor-SM-5EEBM	
Putatively Actionable	Preclinical		Clinical evidence	Rearrangement	TMPRSS2	Fusion	TMPRSS2--ERG			0.0	0.0		Putatively Actionable	Rucaparib	Targeted therapy	Cells which harbored the TMPRSS2-ERG fusion became radiosensitive following radiation and PARP inhibitor, specifically Rucaparib.	Chatterjee P, Choudhary GS, Sharma A, et al. PARP inhibition sensitizes to low dose-rate radiation TMPRSS2-ERG fusion gene-expressing and PTEN-deficient prostate cancer cells. PLoS ONE. 2013;8(4):e60408.	https://doi.org/10.1371/journal.pone.0060408							Putatively Actionable	0.0	A cohort of men with localized prostate cancer was followed and a statistically significant association between the presense of the TMPRSS2-ERG fusion and prostate cancer specific death was observed. Prostate cancer with this fusion may be of a more aggressive phenotype.	Demichelis F, Fall K, Perner S, et al. TMPRSS2:ERG gene fusion associated with lethal prostate cancer in a watchful waiting cohort. Oncogene. 2007;26(31):4596-9.	https://doi.org/10.1038/sj.onc.1210237	0				TMPRSS2--ERG Fusion	0.0	PROS10448-1115154		
Putatively Actionable	Preclinical			Copy Number	FGFR1	Amplification				0.0	0.0		Putatively Actionable	Infigratinib	Targeted therapy	A study of 32 Cancer Cell Line Encyclopedia cell lines demonstrating FGFR1 and FGFR2 amplification demonstrated sensitivity to Infigratinib.	Guagnano V, Kauffmann A, Wohrle S, et al. FGFR genetic alterations predict for sensitivity to NVP-BGJ398, a selective pan-FGFR inhibitor. Cancer Discov. 2012;2(12):1118-33.	https://doi.org/10.1158/2159-8290.CD-12-0210												0				FGFR1 Amplification		PROS10448-1115154	PROS10448-1115154-Tumor-SM-5EEBM	
Putatively Actionable			Clinical evidence	Copy Number	MYC	Amplification				0.0	0.0														Putatively Actionable	0.0	Poor prognosis (< 15%) was observed for patients with amplified MYC with Medulloblastoma.	Ryan SL, Schwalbe EC, Cole M, et al. MYC family amplification and clinical risk-factors interact to predict an extremely poor prognosis in childhood medulloblastoma. Acta Neuropathol. 2012;123(4):501-13.	https://doi.org/10.1007/s00401-011-0923-y	0				MYC Amplification		PROS10448-1115154	PROS10448-1115154-Tumor-SM-5EEBM	
Investigate Actionability - High	Clinical trial			Somatic Variant	ATM	Frameshift	p.LWLEN2490fs	0.1977	86.0	0.0	0.0		Investigate Actionability - High	BAY 1895344	Targeted therapy	The ATR inhibitor BAY 1895344 is tolerated at biologically active doses with anti-tumor activity against cancers with certain DDR defects, including ATM protein loss, in patients with advanced metastatic solid tumors resistant or refractory to standard treatment, with and without DDR defects.	De Bono JS, Tan DSP, Caldwell R, et al. First-in-human trial of the oral ataxia telangiectasia and Rad3-related (ATR) inhibitor BAY 1895344 in patients (pts) with advanced solid tumors. JCO. 2019; 37(15_suppl):3007-3007.	https://10.1200/JCO.2019.37.15_suppl.3007												0	0.0	0.0	0.0	ATM p.LWLEN2490fs (Frameshift)		PROS10448-1115154	PROS10448-1115154-Tumor-SM-5EEBM	PROS10448-1115154-Normal-SM-4YS2D
Investigate Actionability - High			Inferential	Aneuploidy	Whole genome doubling																				Investigate Actionability - High	0.0	WGD was associated with adverse survival pan-cancer in patients with advanced disease and in cancers with heterogeneous clinical outcomes, even following the development of metastasis.	Bielski CM, Zehir A, Penson AV, et al. Genome doubling shapes the evolution and prognosis of advanced cancers Nat Genet. 2018; 50(8):1189-1195.	https://doi.org/10.1038/s41588-018-0165-1	0						PROS10448-1115154		
Investigate Actionability - Low	Preclinical		Clinical evidence	Rearrangement	ERG	Fusion	TMPRSS2--ERG			0.0	0.0		Investigate Actionability - Low	Rucaparib	Targeted therapy	Cells which harbored the TMPRSS2-ERG fusion became radiosensitive following radiation and PARP inhibitor, specifically Rucaparib.	Chatterjee P, Choudhary GS, Sharma A, et al. PARP inhibition sensitizes to low dose-rate radiation TMPRSS2-ERG fusion gene-expressing and PTEN-deficient prostate cancer cells. PLoS ONE. 2013;8(4):e60408.	https://doi.org/10.1371/journal.pone.0060408							Investigate Actionability - Low	0.0	A cohort of men with localized prostate cancer was followed and a statistically significant association between the presense of the TMPRSS2-ERG fusion and prostate cancer specific death was observed. Prostate cancer with this fusion may be of a more aggressive phenotype.	Demichelis F, Fall K, Perner S, et al. TMPRSS2:ERG gene fusion associated with lethal prostate cancer in a watchful waiting cohort. Oncogene. 2007;26(31):4596-9.	https://doi.org/10.1038/sj.onc.1210237	0				TMPRSS2--ERG Fusion	0.0	PROS10448-1115154		
Biologically Relevant				Somatic Variant	POT1	Missense	p.Q16L	0.0428	584.0	0.0	0.0																			0	10.0	0.1	0.0008	POT1 p.Q16L (Missense)		PROS10448-1115154	PROS10448-1115154-Tumor-SM-5EEBM	PROS10448-1115154-Normal-SM-4YS2D
Biologically Relevant				Copy Number	ATM	Deletion				0.0	0.0																			0				ATM Deletion		PROS10448-1115154	PROS10448-1115154-Tumor-SM-5EEBM	
Biologically Relevant				Microsatellite Stability	Supporting variants		PRDM2 p.703_704insP (Insertion), MSH3 p.PPA66del (Deletion)																							0				Supporting variants: PRDM2 p.703_704insP (Insertion), MSH3 p.PPA66del (Deletion)		PROS10448-1115154		
Biologically Relevant				Mutational Signature	COSMIC Signature 1		0.856																							0				COSMIC Signature 1 (86%)		PROS10448-1115154		
